Emergent BioSolutions Receives BARDA Task Order Valued at Up to $30.5 Million to Develop Viral Hemorrhagic Fever Therapeutics

(Released 13 February 2017) Gaithersburg, MD – Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has received a task order from the Biomedical Advanced Research and Development Authority(BARDA) valued at up to $30.5 million to develop monoclonal antibody therapeutics for viral hemorrhagic fever. This task order will utilize the company’s Center for Innovation in Advanced Development and Manufacturing (CIADM) facility located in Baltimore, Maryland. Using monoclonal antibodies from Mapp Biopharmaceutical Inc., the company will conduct technology transfer of process materials and information, perform process and analytical method development, execute small-scale production runs, and perform cGMP cell banking leading to cGMP manufacture of bulk drug substance. The task order consists of a 36-month period of performance with a base task order valued at $7.4 million and options that, if executed, will bring the total task order value over three years to up to $30.5 million.

“Protecting and enhancing life is at the core of Emergent’s mission, and one of the ways by which we are able to fulfill this mission is in partnership with BARDA as it addresses emerging public health threats,” said Adam Havey, executive vice president and president, biodefense division of Emergent BioSolutions. “Emergent’s CIADM is a great example of a public-private partnership that works towards a shared goal. We look forward to successfully executing this task order in collaboration with all parties involved.”    

This is the fourth BARDA Task Order awarded to Emergent under the CIADM program. Since its inception in 2012, Emergent’s CIADM facility has been utilized to respond to public health emergencies including Ebola and Zika.

This Task Order Number HHSO10033004T under contract HHSO100201200004I is funded by BARDA, within the Office of the Assistant Secretary for Preparedness and Response in HHS.

About Emergent BioSolutions
Emergent BioSolutions Inc. is a global life sciences company seeking to protect and enhance life by focusing on providing specialty products for civilian and military populations that address accidental, intentional, and naturally emerging public health threats. Through our work, we envision protecting and enhancing 50 million lives with our products by 2025. Additional information about the company may be found at emergentbiosolutions.com. Follow us @emergentbiosolu.

Investor Contact:
Robert G. Burrows
ice President, Investor Relations
Phone: 240-631-3280
Email: BurrowsR@ebsi.com

Media Contact:
Tracey Schmitt Lintott
Senior Vice President, Global Public Affairs
Phone: 240-631-3281
Email: SchmittT@ebsi.com

Released by Emergent BioSolutions Inc. Click here for source.